Neoadjuvant Tyrosine Kinase Inhibitors

Area of Science:

• Oncology
• Pharmacology
• Surgical Oncology

Background:

• Neoadjuvant tyrosine kinase inhibitor (TKI) therapy is being investigated for its potential to control systemic disease and downstage tumors before surgery.
• Early data from smaller studies suggested promise, but larger trials like NeoADAURA, ALNEO, and NAUTIKA1 are now providing more robust outcomes.

Purpose of the Study:

• To evaluate the safety, efficacy, and impact of neoadjuvant tyrosine kinase inhibitor (TKI) therapy in the context of surgical oncology.
• To compare the outcomes of neoadjuvant TKI therapy with other neoadjuvant treatments, particularly immunotherapy.

Main Methods:

• Review of early results from major clinical trials (NeoADAURA, ALNEO, NAUTIKA1) investigating neoadjuvant TKI therapy.
• Analysis of safety data, surgical timing, tumor downstaging, and pathologic response rates.

Main Results:

• Neoadjuvant TKI therapy has demonstrated a good safety profile and does not typically delay surgical intervention.
• Tumor downstaging has been observed with neoadjuvant TKI use.
• Pathologic response rates are generally lower compared to those achieved with neoadjuvant immunotherapy.
• Current data do not indicate an improvement in overall survival with neoadjuvant TKI therapy.

Conclusions:

• Neoadjuvant TKI therapy is safe and can achieve tumor downstaging, but its pathologic response rates are inferior to immunotherapy.
• There is currently no evidence that neoadjuvant TKI therapy improves survival outcomes.
• The use of neoadjuvant TKI is primarily restricted to clinical trials, though this may evolve with further research.